LRP1 and Its Role in Vascular Health
Author Information
Author(s): Boucher Philippe, Li Wei-Ping, Matz Rachel L., Takayama Yoshiharu, Auwerx Johan, Anderson Richard G.W., Herz Joachim
Primary Institution: Institut Gilbert-Laustriat, UMR 7175 LC-1, Department of Pharmacology; Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Medicale/Université Louis Pasteur, Illkirch, France
Hypothesis
Does LRP1 function as an integrator of TGFβ and PDGF signals in the vascular wall?
Conclusion
Loss of LRP1 in vascular smooth muscle cells leads to increased TGFβ signaling and a Marfan-like syndrome, but treatment with rosiglitazone can reverse these effects.
Supporting Evidence
- Loss of LRP1 in vascular smooth muscle cells leads to a Marfan-like syndrome.
- Treatment with rosiglitazone can reverse the Marfan-like phenotype.
- LRP1 is essential for maintaining vascular wall integrity.
Takeaway
LRP1 helps keep blood vessels healthy, and when it's missing, it can cause problems like Marfan syndrome. A medicine called rosiglitazone can help fix some of these issues.
Methodology
The study used smLRP− mice to investigate the effects of LRP1 loss on vascular health and the impact of rosiglitazone treatment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website